NCT06785298

Fexofenadine as Adjuvant Therapy in Parkinson Disease

Clinical Study to Evaluate the Possible Efficacy and Safety of Fexofenadine in Patients With Parkinson's Disease Treated With Conventional Treatment

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Tanta University · Academic / Other
• Sex: All
• Age: 50 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

Parkinson's disease (PD) is a chronic, progressive neurological disorder characterized by both motor and non-motor symptoms. PD is the second most common neurodegenerative disorder after Alzheimer's disease and the most common movement disorder. PD has age-related pathology; it is present in 1-2% of the population over 60 years of age. The disease is characterized by a triad of disordered voluntary motor activity in the form of bradykinesia (slowness of movement) or even akinesia (absence of movement),rigidity and postural instability, and a resting tremor of the hands and less commonly the feet.

Conditions

• Parkinson Disease

Interventions

Type	Name	Description
DRUG	Levodopa/carbidopa	A dopamine precursor, was first developed for the treatment of PD in the 1960s and continues to be the most-effective therapeutic agent for PD
DRUG	Fexofenadine	Fexofenadine is a second-generation antihistamine that does not penetrate the CNS and has the least CNS side effects among the second-generation antihistamines

Timeline

• Start date: 2024-12-10
• Primary completion: 2026-12-10
• Completion: 2026-12-20
• First posted: 2025-01-21
• Last updated: 2026-01-21

Locations

1 site across 1 country: Egypt